Revexepride

Cat. No.: HY-U00373

CAS No.: 219984-49-3

Molecular Formula: $C_{21}H_{32}ClN_3O_4$

Molecular Weight: 425.95

Target: 5-HT Receptor; Cytochrome P450

Pathway: GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (234.77 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3477 mL	11.7385 mL	23.4769 mL
	5 mM	0.4695 mL	2.3477 mL	4.6954 mL
	10 mM	0.2348 mL	1.1738 mL	2.3477 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatment of gastroesophageal reflux disease.

IC_{50} & Target

5-HT_4 Receptor

CYP3A4

In Vitro

The human CYP isoenzymes are involved in the metabolism of revexepride, which is mainly metabolized in vitro in humans by CYP3A4 (99.9%) with a minor contribution of CYP2D6 (0.1%). Revexepride exhibits direct inhibition of human CYP3A4 in vitro with IC_{50} values of 16-49 μM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. David Pierce, et al. A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. Drug Des Devel Ther. 2015; 9: 1257-1268.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA